Phase II trial of VM-26 in patients with metastatic malignant melanoma.
作者信息
Bellet R E, Catalno R B, Mastrangelo M J, Berd D, Koons L S
出版信息
Cancer Treat Rep. 1978 Mar;62(3):445-7.
PMID:348313
Abstract
摘要
相似文献
1
Phase II trial of VM-26 in patients with metastatic malignant melanoma.
Cancer Treat Rep. 1978 Mar;62(3):445-7.
2
Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
Cancer Treat Rep. 1982 Feb;66(2):405-6.
3
Phase II study of VM-26 in adult malignancies.
Cancer Treat Rep. 1980 Jan;64(1):147-9.
4
Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
Cancer Treat Rep. 1986 Oct;70(10):1231-2.
5
Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
Cancer Treat Rep. 1977 Jan-Feb;61(1):87-8.
6
VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Cancer Treat Rep. 1979 Jan;63(1):7-11.
7
Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
Cancer Treat Rep. 1978 Jul;62(7):993-6.
8
High-dose teniposide for refractory malignancies: a phase I study.
Cancer Treat Rep. 1986 May;70(5):595-8.
9
Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
Cancer Treat Rep. 1986 Feb;70(2):307-8.
10
[Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial].
Nouv Presse Med. 1976 Jun 19;5(25):1571-6.
引用本文的文献
1
VM26: phase I and II studies.
Cancer Chemother Pharmacol. 1982;7(2-3):87-91. doi: 10.1007/BF00254527.
2
The podophyllotoxin derivatives VP16-213 and VM26.
Cancer Chemother Pharmacol. 1982;7(2-3):73-80. doi: 10.1007/BF00254525.
Zotero 插件